With the new corporate minimum tax going into effect Jan. 1, companies are asking the U.S. government for information on its scope and potential impact on certain transactions. Read More...
Motley Fool
Why Medpace Stock Soared Today
Shares of Medpace Holdings (NASDAQ: MEDP) surged 37.7% on Tuesday after the clinical contract research organization (CRO) delivered strong third-quarter results and issued an optimistic financial forecast for the year ahead. Medpace’s revenue jumped 30% year over year to $383.7 million, easily outpacing Wall Street’s estimates of roughly $357 million. The healthcare company, which helps pharmaceutical, biotechnology, and medical device companies conduct clinical trials, also saw its backlog grow by 21% to $2.2 billion as of the end of September.
Add Comment